Licensing Agreement with University of Maryland
for Antiviral Compounds, Including COVID-19

AIkido Pharma Executes Exclusive World-Wide License to Broad Spectrum Antiviral Drug Platform, Includes Coronavirus

On April 14, the Company announced that it has secured an exclusive world-wide license for a broad spectrum antiviral drug platform. The licensed technology is a broadly acting pan-viral inhibitory compound with efficacy against multiple viral pathogens. The technology works to inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

NEW YORK, April 21, 2020 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) (“AIkido” or the “Company”) today announced that on April 13, 2020, the Company executed a Master License Agreement (the “License Agreement”) with the University of Maryland, Baltimore (“UMB”). The License Agreement covers specific antiviral compounds discovered by UMB. The compounds seek to inhibit replication of multiple viruses, including Influenza virus, SARS-CoV, MERS-CoV, Ebolavirus and Marburg virus.

The technology is covered by two patent applications already on file with the United States Patent and Trademark Office. The UMB inventors are Drs. Matthew Frieman, Alexander MacKerell and Stuart Watson. The Company has also executed a Sponsored Research Agreement with UMB to support the development of the technology.

Mr. Anthony Hayes, CEO of AIkido, stated, “We are excited to move forward with this new antiviral platform. The pedigree of the inventors and the institution is first rate. We believe the doctors and UMB are both leaders in the field and are frequently cited in major publications discussing viruses generally, as well as COVID-19. We are proud to partner with them in this critical undertaking.”

Hayes continued, “We have also added significant depth to our board of directors. Our recent capital raise has positioned the Company to comfortably fund current operations and acquire new assets. Management believes that our new board members bring significant capital market and M&A experience, which we plan to leverage. While the world works to overcome the difficult challenges as a result of the pandemic, we at AIkido are excited to look to the future.”


Email Alerts.

Receive the latest news & events.